Jury Awards GSK $235 Million after Teva Added Heart Failure Indication to Generic Coreg

A federal jury awarded GlaxoSmithKline $235 million in a suit against Teva, saying the generics manufacturer infringed on GSK’s patent for the cardiovascular drug Coreg when Teva marketed its generic for chronic heart failure as well as high blood pressure.
Source: Drug Industry Daily